This article utilizes in-house transcriptome sequencing data, bioinformatics analysis, and both in vivo and in vitro experimental validation to provide a comprehensive description of cuproptosis and the role of ts-MHC-II-HLA-DRA in ccRCC immunotherapy. This evidence concerns the gene HLA-DRA and nonpapillary renal cell carcinoma.